CIMERLI vs SUSVIMO

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 20, 2026·How we rate

Possible drug interaction. CIMERLI and SUSVIMO are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	CIMERLI	SUSVIMO
Rating	68/100	70/100
Pharmacy pays	—	—
Type	RX	RX
Active ingredient	RANIBIZUMAB-EQRN	RANIBIZUMAB
Manufacturer	Sandoz	Genentech Inc
Dosage forms	Injectable	Injectable
Drug class	—	Vascular Endothelial Growth Factor Inhibitor
Boxed warning	None	Boxed warning
Treats	Diabetic Retinopathy, Macular Edema, Retinal Vein Occlusion	Diabetic Retinopathy, Macular Edema, Retinal Vein Occlusion

cimerli susvimo

Rating

68/100

70/100

Pharmacy pays

—

Type

Active ingredient

RANIBIZUMAB-EQRN

RANIBIZUMAB

Manufacturer

Sandoz

Genentech Inc

Dosage forms

Injectable

Drug class

—

Vascular Endothelial Growth Factor Inhibitor

Boxed warning

None

Boxed warning

Treats

Diabetic Retinopathy, Macular Edema, Retinal Vein Occlusion

Frequently asked questions

Which is better-rated, Cimerli or Susvimo?

By our independent rating, Susvimo scores higher — 3.5 vs 3.4 out of 5 for Cimerli. Ratings are based on FDA regulatory (recall-safety) data.

What is the difference between Cimerli and Susvimo?

Cimerli contains Ranibizumab-Eqrn, while Susvimo contains Ranibizumab — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.